Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma

British Journal of Cancer

Volumn 108, Issue 9, 2013, Pages 1801-1806

  Maiga S ^a,b,c   Gomez Bougie, P ^a,b,c,d   Bonnaud, S ^a,b,c   Gratas, C ^a,b,c   Moreau, P ^d   Le Gouill, S ^a,b,c,d   Pellat Deceunynck, C ^a,b,c   Amiot, M ^a,b,c  

^a Département de Recherche en Cancérologie Nantes Angers   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UMR 6299   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Cell lines; Cytokines; Growth factors; Lenalidomide; Multiple myeloma

Indexed keywords

INTERLEUKIN 8; LENALIDOMIDE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL FACTOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOLOGIC FACTORS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-8; MULTIPLE MYELOMA; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878573163     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.186     Document Type: Article

References (17)

1. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL. IFM Investigators (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1782-1791.
2. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P (2005) CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 90: 706-707.
3. Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare Jr TL, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N (2011) Biological effects and clinical significance of lenalidomide induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response cancer. Br J Haematol 155: 457-467.
4. Collette M, Descamps G, Pellat-Deceunynck C, Bataille R, Amiot M (2007) Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Eur Cytokine Netw 18: 120-126.
5. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132.
6. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D (2009) Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 69: 7347-7356.
7. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117: 4409-4419.
8. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, Jäger U, Chopra R. (2011) Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 154: 325-336.
9. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1770-1781.
10. Menu E, van Valckenborgh E, van Camp B, Vanderkerken K (2009) The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 115: 49-57.
11. Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M, Pellat-Deceunynck C (2011) A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96: 574-582.
12. Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9: 1625-1630.
13. Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H (2008) Lenalidomide: a new therapy for multiple myeloma. Cancer Treat Rev 34: 283-291.
14. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
15. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
16. Raje N, Hideshima T, Anderson KC (2006) Therapeutic use of immunodulatory drugs in the treatment of multiple myeloma. Expert Rev Anticancer Ther 6: 1239-1247.
17. SprynskiAC, Hose D,Caillot L, Réme T, Shaughnessy Jr JD, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B. (2009) The role of IGF-1as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113: 4614-4626.